PT  - JOURNAL ARTICLE
AU  - Nelson Lee
AU  - Lena Nguyen
AU  - Peter C. Austin
AU  - Kevin A. Brown
AU  - Ramandip Grewal
AU  - Sarah A Buchan
AU  - Sharifa Nasreen
AU  - Jonathan Gubbay
AU  - Kevin L Schwartz
AU  - Mina Tadrous
AU  - Kumanan Wilson
AU  - Sarah E Wilson
AU  - Jeffrey C Kwong
AU  - Canadian Immunization Research Network (CIRN) Provincial Collaborative Network (PCN) investigators
TI  - Protection conferred by COVID-19 vaccination, prior SARS-CoV-2 infection, or hybrid immunity against Omicron-associated severe outcomes among community-dwelling adults
AID  - 10.1101/2023.08.24.23294503
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.08.24.23294503
4099  - http://medrxiv.org/content/early/2023/08/25/2023.08.24.23294503.short
4100  - http://medrxiv.org/content/early/2023/08/25/2023.08.24.23294503.full
AB  - Introduction We assessed protection conferred by COVID-19 vaccines and/or prior SARS-CoV-2 infection against Omicron-associated severe outcomes during successive sublineage-predominant periods.Methods We used a test-negative design to estimate protection by vaccines and/or prior infection against hospitalization/death among community-dwelling, PCR-tested adults aged ≥50 years in Ontario, Canada between January 2, 2022 and June 30, 2023. Multivariable logistic regression was used to estimate the relative change in the odds of hospitalization/death with each vaccine dose (2−5) and/or prior PCR-confirmed SARS-CoV-2 infection (compared with unvaccinated, uninfected subjects) up to 15 months since the last vaccination or infection.Results We included 18,526 cases with Omicron-associated severe outcomes and 90,778 test-negative controls. Vaccine protection was high during BA.1/BA.2 predominance, but was generally <50% during periods of BA.4/BA.5 and BQ/XBB predominance without boosters. A third/fourth dose transiently increased protection during BA.4/BA.5 predominance (third-dose, 6-month: 68%, 95%CI 63%−72%; fourth-dose, 6-month: 80%, 95%CI 77%−83%), but was lower and waned quickly during BQ/XBB predominance (third-dose, 6-month: 59%, 95%CI 48%−67%; 12-month: 49%, 95%CI 41%−56%; fourth-dose, 6-month: 62%, 95%CI 56%−68%, 12-months: 51%, 95%CI 41%−56%). Hybrid immunity conferred nearly 90% protection throughout BA.1/BA.2 and BA.4/BA.5 predominance, but was reduced during BQ/XBB predominance (third-dose, 6-month: 60%, 95%CI 36%−75%; fourth-dose, 6-month: 63%, 95%CI 42%−76%). Protection was restored with a fifth dose (bivalent; 6-month: 91%, 95%CI 79%−96%). Prior infection alone did not confer lasting protection.Conclusion Protection from COVID-19 vaccines and/or prior SARS-CoV-2 infections against severe outcomes is reduced when immune-evasive variants/subvariants emerge and may also wane over time. Our findings support a variant-adapted booster vaccination strategy with periodic review.Competing Interest StatementNelson Lee has previously received honoraria for consultancy work, speaking in educational programs, and/or travel support from: Shionogi Inc., Gilead Sciences Canada Inc., Janssen Inc., GlaxoSmithKline plc., Sanofi Pasteur Ltd., F. Hoffmann-La Roche Ltd., Genentech Inc., CIDARA Therapeutics Inc., Clarion Healthcare, bioStrategies, Technospert, Aligos; all unrelated to this work. Kumanan Wilson is a shareholder and board member of CANImmunize Inc. and has served on independent scientific advisory boards for Medicago and Moderna.Funding StatementThis work was supported by funding from the Canadian Immunization Research Network (CIRN) through a grant from the Public Health Agency of Canada and the Canadian Institutes of Health Research (CNF 151944), and also by funding from the Public Health Agency of Canada, through the Vaccine Surveillance Working Party and the COVID-19 Immunity Task Force. This study was supported by Public Health Ontario and by ICES, which is funded by an annual grant from the Ontario Ministry of Health (MOH) and Ministry of Long-Term Care (MLTC). This work was also supported by the Ontario Health Data Platform (OHDP), a Province of Ontario initiative to support Ontario's ongoing response to COVID-19 and its related impacts. Jeffrey C. Kwong is supported by a Clinician-Scientist Award from the University of Toronto Department of Family and Community Medicine. The study sponsors did not participate in the design and conduct of the study; collection, management, analysis and interpretation of the data; preparation, review or approval of the manuscript; or the decision to submit the manuscript for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:We used provincial data from ICES (formerly the Institute for Clinical Evaluative Sciences), an independent, non-profit research institute whose legal status under Ontario's health information privacy law allows it to collect and analyze health care and demographic data for health system evaluation and improvement. As described in our previous studies [reference 3,4,5,9], SARS-CoV-2 laboratory testing, COVID-19 surveillance, COVID-19 vaccination, and health administrative datasets were linked using unique encoded identifiers and analyzed at ICES. The use of the data in this study is authorized under section 45 of Ontario's Personal Health Information Protection Act and does not require review by a research ethics board. ICES is a prescribed entity under Ontario's Personal Health Information Protection Act (PHIPA). Section 45 of PHIPA authorizes ICES to collect personal health information, without consent, for the purpose of analysis or compiling statistical information with respect to the management of, evaluation or monitoring of, the allocation of resources to or planning for all or part of the health system. Projects that use data collected by ICES under section 45 of PHIPA, and use no other data, are exempt from REB review. The use of the data in this project is authorized under section 45 and approved by ICES' Privacy and Legal Office.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript